

Jennifer G Goldman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7121/jennifer-g-goldman-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers

8,440
citations

35
h-index

79
g-index

79
ext. papers

10,515
ext. citations

6.1
avg, IF

5.65
L-index

#	Paper	IF	Citations
77	Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures.. <i>Npj Parkinson's Disease</i> , 2022 , 8, 30	9.7	2
76	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 479-483	2.2	0
75	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.. <i>Frontiers in Neurology</i> , 2021 , 12, 805135	4.1	1
74	Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 124	9	1
73	Twelve Drummers Drumming With Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 6	2	1
72	Huntington disease 2021 , 371-400.e14		
71	Peripheral electrical stimulation to reduce pathological tremor: a review. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2021 , 18, 33	5.3	8
70	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 128, 367-382	9	3
69	Nonmotor problems in Parkinson disease 2021 , 234-248.e7		
68	Parkinsonism 2021 , 82-120.e21		
67	Creating a patient-centered guide to navigating cognitive change in Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041115	1.2	
66	The complexity of DLB: U.S.-based Dementia with Lewy Body Consortium. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042846	1.2	
65	Shared imaging biomarkers across Alzheimer's and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046542	1.2	
64	Integrated Care in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Movement Disorders</i> , 2020 , 35, 1509-1531	7	25
63	Treatment of Nonmotor Symptoms Associated with Parkinson Disease. <i>Neurologic Clinics</i> , 2020 , 38, 269-292	3.8	14
62	Cognitive Impairment and Dementia in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020 , 36, 365-377	3.8	24
61	Validation of an Online Screener, the Mediterranean Eating Pattern for Americans-III in Older Patients with Parkinson's Disease. <i>Journal of Nutrition in Gerontology and Geriatrics</i> , 2020 , 39, 30-43	2.1	2

60	The effects of dual-task cognitive interference on gait and turning in Huntington's disease. <i>PLoS ONE</i> , 2020 , 15, e0226827	3.7	9
59	Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 137	9	10
58	α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. <i>Nature Communications</i> , 2020 , 11, 1875	17.4	102
57	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020 , 94, 743-755	35	151
56	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 23	9	2
55	The Effects of Dual-Task Cognitive Interference and Environmental Challenges on Balance in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 202-212	2.2	17
54	Acceptability and Reliability of an Online Version of the MEPA III Screener IN Parkinson'S Participants (P01-010-19). <i>Current Developments in Nutrition</i> , 2019 , 3,	0.4	78
53	Motor phenotype classification in moderate to advanced PD in BioFIND study. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 178-183	3.6	11
52	High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra. <i>Radiology</i> , 2019 , 291, 149-157	20.5	15
51	Risk of Parkinson's disease dementia related to level I MDS PD-MCI. <i>Movement Disorders</i> , 2019 , 34, 430-435	435	21
50	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018 , 33, 499-500	7	0
49	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018 , 33, 503-510	7	33
48	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018 , 33, 528-536	7	16
47	Reply To: Detection of Alpha-Synuclein in Saliva: The Importance of Preanalytical Assessment. <i>Movement Disorders</i> , 2018 , 33, 1031	7	1
46	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018 , 33, 208-218	7	80
45	White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease. <i>Neurology</i> , 2018 , 91, e2244-e2255	6.5	31
44	Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1760-1768	7	10
43	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018 , 33, 1750-1759	7	22

42	Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson's Disease</i> , 2018 , 4, 19	9.7	72
41	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. <i>Movement Disorders</i> , 2018 , 33, 282-288	7	78
40	Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. <i>Neurology</i> , 2017 , 88, 1265-1272	6.5	41
39	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2017 , 89, 88-100	6.5	1691
38	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017 , 32, 1056-1065	7	75
37	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016 , 73, 1217-1224	17.2	120
36	GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 95-102	7	113
35	β-synuclein genetic variability: A biomarker for dementia in Parkinson disease. <i>Annals of Neurology</i> , 2016 , 79, 991-9	9.4	64
34	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016 , 31, 1619-1622	7	43
33	Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 11-22	7	21
32	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. <i>Movement Disorders</i> , 2016 , 31, 924-32	7	36
31	Functional Brain Activity Relates to 0-3 and 3-8 Hz Force Oscillations in Essential Tremor. <i>Cerebral Cortex</i> , 2015 , 25, 4191-202	5.1	54
30	Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2015 , 5, 425-43	2.8	19
29	Writer's cramp. <i>Toxicon</i> , 2015 , 107, 98-104	2.8	6
28	Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. <i>Movement Disorders</i> , 2015 , 30, 1657-63	7	107
27	Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests?. <i>Movement Disorders</i> , 2015 , 30, 402-6	7	86
26	Advances in the treatment of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1471-89	7	50
25	Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. <i>Brain</i> , 2014 , 137, 849-59	11.2	103

24	The spectrum of cognitive impairment in Lewy body diseases. <i>Movement Disorders</i> , 2014 , 29, 608-21	7	89
23	Treatment of psychosis and dementia in Parkinson's disease. <i>Current Treatment Options in Neurology</i> , 2014 , 16, 281	4.4	76
22	Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1135-9	3.6	33
21	Parkinson's disease mild cognitive impairment: application and validation of the criteria. <i>Journal of Parkinson's Disease</i> , 2014 , 4, 131-7	5.3	42
20	Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable. <i>Journal of Parkinson's Disease</i> , 2014 , 4, 585-9	5.3	14
19	Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. <i>Movement Disorders</i> , 2014 , 29, 1252-7	7	6
18	Premotor and nonmotor features of Parkinson's disease. <i>Current Opinion in Neurology</i> , 2014 , 27, 434-41	7.1	195
17	Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. <i>Neurobiology of Disease</i> , 2014 , 69, 1-14	7.5	47
16	Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 806-11	3.6	50
15	Clinical features of neurodegeneration with brain iron accumulation due to a C19orf12 gene mutation. <i>Movement Disorders</i> , 2013 , 28, 1462-3	7	13
14	Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 1972-9	7	78
13	Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. <i>Movement Disorders</i> , 2012 , 27, 248-53	7	38
12	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012 , 27, 349-56	7	1373
11	Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. <i>Movement Disorders</i> , 2012 , 27, 727-34	7	39
10	Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 1129-36	7	76
9	An update expert opinion on management and research strategies in Parkinson's disease psychosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2009-24	4	29
8	New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. <i>Parkinson's Disease</i> , 2011 , 2011, 675630	2.6	7
7	Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. <i>Movement Disorders</i> , 2011 , 26, 1781-2	7	12

6	MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. <i>Movement Disorders</i> , 2011 , 26, 1814-24	7	527
5	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 2501-7	7	124
4	Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. <i>Movement Disorders</i> , 2008 , 23, 2248-50	7	66
3	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1689-707; quiz 1837	7	1968
2	Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. <i>Archives of Neurology</i> , 2004 , 61, 1280-4		44
1	Treatment of dystonia. <i>Clinical Neuropharmacology</i> , 2003 , 26, 102-8	1.4	25